表达工程化刺突蛋白的腺病毒疫苗经黏膜递送通过诱导Th1和Th2免疫预防SARS-CoV-2感染
在啮齿动物模型中测试表达SARS-CoV-2全长或膜截短刺突蛋白的重组人5型腺病毒(AdCoV2-S或AdCoV2-SdTM)经鼻内或皮下免疫的 Efficacy。鼻内递送可诱导血清和黏膜IgG/IgA,且抗体水平高于皮下注射;鼻内免疫以IgG1(Th2)为主,皮下免疫以IgG2a(Th1)为主,两者均激活Th1/Th2免疫。AdCoV2-S和AdCoV2-SdTM显著防止体重下降并降低仓鼠肺病毒载量,鼻内或皮下免疫均减少肺部炎症。
要点
- 鼻内递送腺病毒疫苗可诱导血清和黏膜抗SARS-CoV-2 IgG和IgA。
- 鼻内AdCoV2-S诱导的结合和中和抗体水平高于皮下注射。
- 鼻内免疫以IgG1(Th2)为主,皮下免疫以IgG2a(Th1)为主,均激活Th1和Th2免疫。
核心结论
- 鼻内递送AdCoV2-S疫苗在预防SARS-CoV-2感染方面安全且有效。
研究设计与样本
- 在啮齿动物模型中测试表达SARS-CoV-2全长或膜截短刺突蛋白的重组人5型腺病毒(AdCoV2-S或AdCoV2-SdTM)经鼻内或皮下免疫的Efficacy。
主要发现
- 鼻内递送腺病毒疫苗可诱导血清和黏膜(阴道洗液和支气管肺泡灌洗液)中的抗SARS-CoV-2 IgG和IgA。
- 皮下注射AdCoV2-S诱导血清抗SARS-CoV-2 IgG,但不诱导阴道洗液和支气管肺泡灌洗液中的IgA。
- 鼻内给予AdCoV2-S诱导的抗SARS-CoV-2结合和中和抗体水平高于皮下注射。
- 鼻内给予AdCoV2-SdTM诱导的抗体反应低于鼻内给予AdCoV2-S。
- 鼻内或皮下给予AdCoV2-S诱导的抗S抗体反应不受预存血清抗Ad抗体的影响。
关键数值与推荐
- 鼻内免疫血清中S特异性IgG1(代表Th2介导的体液反应)占主导,而皮下免疫血清中更多IgG2a(代表Th1介导的细胞反应)。
- 在鼻内和皮下AdCoV2-S组中均观察到脾Th1和Th2细胞中S特异性IFN-ɣ和IL-4的激活,表明Th1和Th2免疫被激活。
- AdCoV2-S和AdCoV2-SdTM显著防止仓鼠体重下降并降低肺部病毒载量。
- 鼻内或皮下免疫AdCoV-S的仓鼠在SARS-CoV-2攻击后肺部炎症减少。
- 鼻内免疫AdCoV-S的支气管肺泡灌洗液中检测到Th1细胞因子分泌,但未检测到炎症细胞因子。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A series of recombinant human type 5 adenoviruses that express the full-length or membrane-truncated spike protein (S) of SARS-CoV-2 (AdCoV2-S or AdCoV2-SdTM, respectively) was tested the efficacy against SARS-CoV-2 via intranasal (i.n.) or subcutaneous (s.c.) immunization in a rodent model. Mucosal delivery of adenovirus (Ad) vaccines could induce anti-SARS-CoV-2 IgG and IgA in the serum and in the mucosal, respectively as indicated by vaginal wash (vw) and bronchoalveolar lavage fluid (BALF). Serum anti-SARS-CoV-2 IgG but not IgA in the vw and BALF was induced by AdCoV2-S s.c.. Administration of AdCoV2-S i.n. was able to induce higher anti-SARS-CoV-2 binding and neutralizing antibody levels than s.c. injection. AdCoV2-SdTM i.n. induced a lower antibody responses than AdCoV2-S i.n.. Induced anti-S antibody responses by AdCoV2-S via i.n. or s.c. were not influenced by the pre-existing serum anti-Ad antibody. Novelty, S-specific IgG1 which represented Th2-mediated humoral response was dominantly induced in Ad i.n.-immunized serum in contrast to more IgG2a which represented Th1-mediated cellular response found in Ad s.c.-immunized serum. The activation of S-specific IFN-ɣ and IL-4 in splenic Th1 and Th2 cells, respectively, was observed in the AdCoV2-S i.n. and s.c. groups, indicating the Th1 and Th2 immunity were activated. AdCoV2-S and AdCoV2-SdTM significantly prevented body weight loss and reduced pulmonary viral loads in hamsters. A reduction in inflammation in the lungs was observed in AdCoV-S via i.n. or s.c.-immunized hamsters following a SARS-CoV-2 challenge. It correlated to Th1 cytokine but no inflammatory cytokines secretions found in AdCoV-S i.n. -immunized BALF. These results indicate that intranasal delivery of AdCoV2-S vaccines is safe and potent at preventing SARS-CoV-2 infections.
引用
- Chung NH, Chen YC, Yang SJ, et al. Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein. Vaccine. 2021. PMID: 34952759. doi:10.1016/j.vaccine.2021.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。